Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group

Oncology
S MonfardiniJ F Smyth

Abstract

Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2'-deoxycoformycin, dCF) 4mg/m2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneou...Continue Reading

Citations

Mar 28, 2006·Future Oncology·Anthony D Ho, Manfred Hensel
Dec 3, 2005·Leukemia & Lymphoma·Fadi BraitehRazelle Kurzrock
Jan 27, 2016·Critical Reviews in Oncology/hematology·Pier Luigi ZinzaniStefano Pileri
Jan 2, 2007·Cancer Letters·Amit W Panwalkar, James O Armitage
Dec 29, 2006·Pharmacotherapy·Jeffrey J Bruno, Todd W Canada
Dec 1, 2007·Hematological Oncology·Delvys Rodriguez-AbreuEmanuele Zucca
Jun 21, 2005·Blood Reviews·Farhad Ravandi, Susan O'Brien
Mar 22, 2006·Seminars in Hematology·Nicholas Di Bella, Farhad Ravandi
Sep 10, 2014·Cancer Treatment Reviews·Bertrand CoiffierPier Luigi Zinzani
Jan 20, 2007·British Journal of Haematology·Nam H DangLuis Fayad
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip WentStefano A Pileri
Oct 8, 2005·Blood·Mujahid A RizviSteven T Rosen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.